tazarotene Search Results


bismaleimidoethane bmoe thermo scientific  (Thermo Fisher)
93
Thermo Fisher bismaleimidoethane bmoe thermo scientific
Bismaleimidoethane Bmoe Thermo Scientific, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bismaleimidoethane bmoe thermo scientific/product/Thermo Fisher
Average 93 stars, based on 1 article reviews
bismaleimidoethane bmoe thermo scientific - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
tazarotene  (MedChemExpress)
90
MedChemExpress tazarotene
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Tazarotene, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene/product/MedChemExpress
Average 90 stars, based on 1 article reviews
tazarotene - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tazarotene  (Selleck Chemicals)
90
Selleck Chemicals tazarotene
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Tazarotene, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene/product/Selleck Chemicals
Average 90 stars, based on 1 article reviews
tazarotene - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
chemical vendors  (MedChemExpress)
90
MedChemExpress chemical vendors
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Chemical Vendors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/chemical vendors/product/MedChemExpress
Average 90 stars, based on 1 article reviews
chemical vendors - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant human chemerin  (MedChemExpress)
92
MedChemExpress recombinant human chemerin
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Recombinant Human Chemerin, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human chemerin/product/MedChemExpress
Average 92 stars, based on 1 article reviews
recombinant human chemerin - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
ek1329  (Boster Bio)
90
Boster Bio ek1329
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Ek1329, supplied by Boster Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ek1329/product/Boster Bio
Average 90 stars, based on 1 article reviews
ek1329 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
halobetasol propionate and tazarotene lotion 0.01%/0.045  (Ortho Dermatologics)
90
Ortho Dermatologics halobetasol propionate and tazarotene lotion 0.01%/0.045
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Halobetasol Propionate And Tazarotene Lotion 0.01%/0.045, supplied by Ortho Dermatologics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/halobetasol propionate and tazarotene lotion 0.01%/0.045/product/Ortho Dermatologics
Average 90 stars, based on 1 article reviews
halobetasol propionate and tazarotene lotion 0.01%/0.045 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tazarotene 0.1% foam  (Mayne Pharma)
90
Mayne Pharma tazarotene 0.1% foam
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Tazarotene 0.1% Foam, supplied by Mayne Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene 0.1% foam/product/Mayne Pharma
Average 90 stars, based on 1 article reviews
tazarotene 0.1% foam - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tazarotene 0.1% cream  (Allergan)
90
Allergan tazarotene 0.1% cream
Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), <t>tazarotene,</t> or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.
Tazarotene 0.1% Cream, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene 0.1% cream/product/Allergan
Average 90 stars, based on 1 article reviews
tazarotene 0.1% cream - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tazarotene  (Allergan)
90
Allergan tazarotene
Summary of trial outcome and <t> tazarotene </t> dose levels (mg day −1 )
Tazarotene, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene/product/Allergan
Average 90 stars, based on 1 article reviews
tazarotene - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
tazarotene gel  (HuaPont Pharmaceutical Co Ltd)
90
HuaPont Pharmaceutical Co Ltd tazarotene gel
Summary of trial outcome and <t> tazarotene </t> dose levels (mg day −1 )
Tazarotene Gel, supplied by HuaPont Pharmaceutical Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/tazarotene gel/product/HuaPont Pharmaceutical Co Ltd
Average 90 stars, based on 1 article reviews
tazarotene gel - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
retinoids tazarotene  (Allergan)
90
Allergan retinoids tazarotene
Summary of trial outcome and <t> tazarotene </t> dose levels (mg day −1 )
Retinoids Tazarotene, supplied by Allergan, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/retinoids tazarotene/product/Allergan
Average 90 stars, based on 1 article reviews
retinoids tazarotene - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), tazarotene, or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.

Journal: Advanced Science

Article Title: Synthetic Retinoid Kills Drug‐Resistant Cancer Stem Cells via Inducing RAR γ ‐Translocation‐Mediated Tension Reduction and Chromatin Decondensation

doi: 10.1002/advs.202203173

Figure Lengend Snippet: Retinoid WYC‐209 is highly potent in inducing tumor cell apoptosis. A) The IC 50 values of conventional drugs (all‐trans retinoic acid (ATRA), tazarotene, or cisplatin) or WYC‐209 for B16‐F1 TRCs were determined in the MTT assay after treatment for 48 h. B,C) B16 TRCs were treated with ATRA, tazarotene, cisplatin at 10 and 100 µ m and WYC‐209 at 10 µ m for 24 h, then the cell apoptotic ratio analyzed by FITC–Annexin‐V and PI apoptosis detection kit. Representative images of flow cytometry data (B) and quantification data of apoptotic cells ratio (C). Apoptotic cells (%) = 100% − (Annexin‐V − PI − )%. D–K) Representative western blot images (D, F, H, J) and quantification (E, G, I, K) of relative γ H2AX, C‐PARP, and C‐Caspase3 expression of B16 TRCs treated with 100 µ m ATRA, 100 µ m tazarotene, 100 µ m cisplatin, or 10 µ m WYC‐209 for various durations. Mean ± s.e.m.; three independent experiments. One‐way ANOVA testing followed by a Tukey post‐hoc test when appropriate was used for statistics. * p < 0.05; ** p < 0.01; *** p < 0.001; ns = not significantly different.

Article Snippet: Cisplatin (HY‐17394), tazarotene (HY‐15388), and ATRA (HY‐14649) were obtained from MedChem Express (NJ, USA).

Techniques: MTT Assay, Flow Cytometry, Western Blot, Expressing

Summary of trial outcome and tazarotene dose levels (mg day −1 )

Journal: British Journal of Cancer

Article Title: A phase 1 study of tazarotene in adults with advanced cancer

doi: 10.1038/sj.bjc.6601169

Figure Lengend Snippet: Summary of trial outcome and tazarotene dose levels (mg day −1 )

Article Snippet: Tazarotene was supplied by Allergan as soft gelatin capsules in a liquid triglyceride vehicle containing either 0.7 or 2.1 mg tazarotene.

Techniques:

Symptomatic adverse events and biochemical abnormalities of frequency≥10%, related to tazarotene treatment

Journal: British Journal of Cancer

Article Title: A phase 1 study of tazarotene in adults with advanced cancer

doi: 10.1038/sj.bjc.6601169

Figure Lengend Snippet: Symptomatic adverse events and biochemical abnormalities of frequency≥10%, related to tazarotene treatment

Article Snippet: Tazarotene was supplied by Allergan as soft gelatin capsules in a liquid triglyceride vehicle containing either 0.7 or 2.1 mg tazarotene.

Techniques:

(A ) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. ( B ) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. ( C ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. ( D ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. ( E ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients at week 4. ( F ) Dose-normalized (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in five cancer patients at week 4.

Journal: British Journal of Cancer

Article Title: A phase 1 study of tazarotene in adults with advanced cancer

doi: 10.1038/sj.bjc.6601169

Figure Lengend Snippet: (A ) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. ( B ) Plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. ( C ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients on day 0. ( D ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in seven cancer patients on day 0. ( E ) Dose-normalised (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 1.4 mg tazarotene in six cancer patients at week 4. ( F ) Dose-normalized (1 mg) plasma concentrations (mean±s.e.m.) of tazarotenic acid following oral administration of 25.2 mg tazarotene in five cancer patients at week 4.

Article Snippet: Tazarotene was supplied by Allergan as soft gelatin capsules in a liquid triglyceride vehicle containing either 0.7 or 2.1 mg tazarotene.

Techniques:

Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks

Journal: British Journal of Cancer

Article Title: A phase 1 study of tazarotene in adults with advanced cancer

doi: 10.1038/sj.bjc.6601169

Figure Lengend Snippet: Summary of the pharmacokinetic parameters of tazarotenic acid following single-dose oral administration of Tazarotene on day 0 and at 12 weeks

Article Snippet: Tazarotene was supplied by Allergan as soft gelatin capsules in a liquid triglyceride vehicle containing either 0.7 or 2.1 mg tazarotene.

Techniques: